AKT1 and prostate cancer: Our hypothesis was that as P529 inhibits the Akt pathway (Xue et al, 2008), which is critically involved in radioresistance (McKenna and Muschel, 2003; Cheng et al, 2006) and lacks in vivo toxicity (Xue et al, 2008), the use of this drug would be an excellent novel candidate to enhance the effect of RT in prostate cancer.